GlassScriptPhysician profile
Krunal Patel
NPI 1003251356
$4,141.93
in general payments reported to CMS, 2019-2025
29 companies · $997 in 2025
The $997 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $132 · 2021: $405 · 2022: $509 · 2023: $682 · 2024: $1,213 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,835 · Education: $56.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,834.81 |
| Education | $56.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,156.18 | 2019-2025 | |
| Gilead Sciences, INC. | $415.92 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $411.44 | 2019-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $281.07 | 2022-2025 | |
| Janssen Biotech, INC. | $196.33 | 2021-2025 | Tremfya, Stelara, Remicade |
| Braintree Laboratories, INC. | $181.08 | 2019-2025 | Sutab, Suflave |
| Lilly USA, LLC | $179.17 | 2023-2025 | Omvoh |
| Daiichi Sankyo INC. | $159.47 | 2021-2024 | Injectafer |
| Intuitive Surgical, INC. | $158.67 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.86 | 2019-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2023-2025 | Dupixent |
| Pfizer INC. | $109.62 | 2022-2025 | |
| Celltrion USA INC. | $100.28 | 2023-2025 | Yuflyma, Vegzelma |
| Ironwood Pharmaceuticals, INC | $87.46 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $59.78 | 2023-2024 | Dificid |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $53.79 | 2021 | |
| Phathom Pharmaceuticals, INC. | $47.39 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $46.74 | 2024 | Sucraid |
| Celgene Corporation | $46.14 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $23.19 | 2025 | Zenpep |
| Pharmacosmos Therapeutics INC. | $22.28 | 2022 | |
| Enterra Medical, INC. | $20.00 | 2024 | |
| Capsovision, INC. | $17.30 | 2024 | Capsocam Plus |
| Inspire Medical Systems, INC. | $17.27 | 2023 | Inspire |
| Sandoz INC. | $15.79 | 2023 | Treprostinil |
| Ardelyx, INC. | $14.63 | 2022 | |
| Novo Nordisk INC | $14.53 | 2025 | Wegovy |
| Amgen INC. | $14.38 | 2025 | Uplizna |
| Boston Scientific Corporation | $13.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krunal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.